In Brief: FDA reform
This article was originally published in The Tan Sheet
Executive Summary
FDA reform: House Commerce Committee FDA reform legislation expected to be marked up by mid-July, with the goal of having a bill through the House in time for conference before the August recess, set to begin Aug. 2. The Senate FDA Reform/Prescription Drug User Fee Act reauthorization bill (S 830) was reported out of committee June 18 ("The Tan Sheet" June 23, p. 14). The House continues to pursue a two-track approach to FDA reform, with medical device-related reform included in a separate bill from PDUFA/drug reform. Senate floor debate on S 830 is expected in mid-July. The drafting process for the Commerce Committee bill is expected to be completed during the June 28-July 7 recess. The committee mark-up may be of Rep. Richard Burr's (R-N.C.) reintroduced drug reform bill (HR 3199) ("The Tan Sheet" Jan. 27, p. 22)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning